Company: Zogenix [1]
Based: San Diego, CA
Amount: $78.8M
Investors: Abingworth Management, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Undisclosed Investor
Scoop: Zogenix is developing CNS disorders and pain treatments. In December 2007 the company submitted an NDA for sumatriptan DosePro, a needle-free, disposable, subcutaneous delivery system for migraine. Zogenix is also working on a Phase III controlled release opioid product it in-licensed from Elan.
More News:
Zogenix gains $60M in new VC funds. Report [2]
Zogenix raises $18M in preferred stock financing. Report [3]
Links:
[1] http://www.zogenix.com/
[2] http://www.fiercebiotech.com/story/zogenix-gains-60m-in-new-vc-funds/2006-08-28
[3] http://www.fiercebiotech.com/press-releases/zogenix-raises-18-million-preferred-stock-financing
[4] http://www.fiercebiotech.com/special-reports/top-20-venture-capital-deals-2007
[5] http://www.fiercebiotech.com/special-reports/ception-therapeutics-top-20-vc-deals-2007